MARKET

PHIO

PHIO

Phio Pharmaceuticals Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.100
-0.220
-9.48%
Closed 16:00 03/27 EDT
OPEN
2.390
PREV CLOSE
2.320
HIGH
2.390
LOW
2.020
VOLUME
69.86K
TURNOVER
--
52 WEEK HIGH
28.88
52 WEEK LOW
2.010
MARKET CAP
5.18M
P/E (TTM)
-0.0019
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PHIO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PHIO stock price target is 2.000 with a high estimate of 2.000 and a low estimate of 2.000.

EPS

PHIO News

More
  • Phio Pharmaceuticals reports Q4 results
  • seekingalpha · 2d ago
  • Phio Pharmaceuticals Reports Year End 2019 Financial Results and Provides Business Update
  • PR Newswire · 3d ago
  • NNVC, PHIO among premarket gainers
  • Seeking Alpha - Article · 03/16 13:16
  • The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
  • Benzinga · 03/13 11:52

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About PHIO

Phio Pharmaceuticals Corp, formerly RXi Pharmaceuticals Corporation, is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) (sd-rxRNA) therapeutic platform. The Company’s focuses on developing sd-rxRNA therapeutic compounds to be used in the context of adoptive cell transfer by targeting checkpoints or other gene targets, or to be used in immunotherapy following intratumoral injection. The Company’s pipeline include RXI-762 and RXI-804. Its sd-rxRNA compounds are designed to down-regulate the expression of a specific gene that may be over-expressed in a disease condition. The Company is developing RXI-762 for the treatment of Melanoma, Ovarian cancer and other indications. RXI-804 is an sd-rxRNA compound that is designed to suppress the expression of immune checkpoint protein, TIGIT.
More

Webull offers kinds of Phio Pharmaceuticals Corp stock information, including NASDAQ:PHIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHIO stock news, and many more online research tools to help you make informed decisions.